Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;72(3):449-55.
doi: 10.1016/j.jaad.2014.12.009. Epub 2015 Jan 14.

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis

Affiliations

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis

David F Fiorentino et al. J Am Acad Dermatol. 2015 Mar.

Abstract

Background: Antibodies against transcriptional intermediary factor (TIF)-1γ are associated with malignancy in dermatomyositis (DM). Identification of clinical findings associated with anti-TIF-1γ antibodies in DM is a high priority for both patient diagnosis and risk assessment.

Objective: We sought to define the clinical phenotype of patients with anti-TIF-1γ DM.

Methods: Using a novel, sensitive, and specific assay for anti-TIF-1γ antibodies, we retrospectively tested plasma from 134 adult patients with DM and examined associations between anti-TIF-1γ antibodies and particular clinical and laboratory features.

Results: In all, 55 (41%) patients had autoantibodies to TIF-1γ. Anti-TIF-1γ positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia. Patients with TIF-1γ autoantibodies had more extensive skin involvement, and some patients manifested characteristic findings including palmar hyperkeratotic papules, psoriasis-like lesions and a novel finding of hypopigmented and telangiectatic ("red on white") patches.

Limitations: This was a retrospective study from a single tertiary referral center.

Conclusion: TIF-1γ is the most commonly targeted DM-specific autoantigen in adults in a large US cohort. Although these patients tend to have less systemic involvement, their skin disease is often extensive and characteristic. Recognition of cutaneous findings in anti-TIF-1γ positive patients may allow more accurate and timely diagnosis and effective treatment of patients with DM.

Keywords: Cutaneous Dermatomyositis Assessment and Severity Index; autoantibodies; dermatomyositis; malignancy; phenotype; transcriptional intermediary factor-1γ.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None declared.

Figures

Fig. 1
Fig. 1
A, Psoriasiform plaque from a patient with dermatomyositis (DM) and anti-transcriptional intermediary factor (TIF)-1γ antibodies but no malignancy. Well-demarcated, erythematous plaque with hyperkeratotic scale on the abdomen. B, Hyperkeratotic Gottron papules from a patient with DM and anti-TIF-1γ antibodies. Thick plaques with micaceous scale over the joints of the back of hand. C, “Red on white” patch seen in a patient with DM. Hypopigmented patch on the forehead with intervening, follicular, erythematous, and telangiectatic macules. This patient was found to have anti-TIF-1γ antibodies but no malignancy. D, Hyperkeratotic papules on the palms from a patient with DM and anti-TIF-1γ antibodies. Hyperkeratotic and verrucous papules in a background of blanchable reticulated erythematous macules on the index finger without associated internal malignancy.

References

    1. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep. 2006;8:196–203. - PubMed
    1. Ghirardello A, Bassi N, Palma L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2013;15:335. - PubMed
    1. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:209. - PMC - PubMed
    1. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689. - PubMed
    1. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology. 2007;46:25–28. - PubMed